Bethany Sensenig
CIK: 0001899935
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 11, 2026KALV
KalVista Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
45K shares- - Apr 16, 2026ACOG
Alpha Cognition Inc.
Award(A)Direct5.5K shares- - Feb 19, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct4.5K shares- - Feb 19, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $50.31$61K - Feb 19, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct3.3K shares at avg. $51.27$167K - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectDirector Stock Option (Right to Buy)
5K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
3K shares- - Oct 1, 2025KALV
KalVista Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Aug 14, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct5.4K shares at avg. $42.25$227K - Feb 22, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Units
5.4K shares- - Feb 22, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct5.4K shares- - Feb 19, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectDirector Stock Option (Right to Buy)
7.3K shares- - Feb 19, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
4.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  KALV KalVista Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| Apr 16, 2026 |  ACOG Alpha Cognition Inc. | Award(A) | 5,489 | - | $0 | Direct |
| Feb 19, 2026 |  SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 4,475 | - | $0 | Direct |
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 1,217 | $50.31 | $61,227 | Direct |
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 3,258 | $51.27 | $167,038 | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Director Stock Option (Right to Buy) | 4,977 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 2,989 | - | - | Direct |
| Oct 1, 2025 | KALV KalVista Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 14, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 5,369 | $42.25 | $226,840 | Direct |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Units | 5,369 | - | - | Direct |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 5,369 | - | - | Direct |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Director Stock Option (Right to Buy) | 7,296 | - | - | Direct |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 4,475 | - | - | Direct |
1-13 of 13 transactions
About Sensenig Bethany
Sensenig Bethany (SEC CIK 0001899935) files insider reports with the SEC as Director of KalVista Pharmaceuticals, Inc. (KALV), Director of Alpha Cognition Inc. (ACOG) and Director of SUPERNUS PHARMACEUTICALS, INC. (SUPN).
Signal8 holds 10 ownership filings by Sensenig Bethany (2 Form 3, 8 Form 4), filed between Feb 21, 2025 and Jun 11, 2026. Those filings report 13 transactions, from Feb 19, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Sensenig Bethany's filings is in FRAMINGHAM, MA.
Recent filings by Sensenig Bethany
- Jun 11, 2026: Disposition to issuer transaction of KALV derivative securities (Form 4, code D).
- Apr 16, 2026: Grant or award of ACOG shares (Form 4, code A).
- Feb 19, 2026: Option exercise of SUPN shares (Form 4, code M).
- Feb 19, 2026: Open-market sales of SUPN shares (2 lines, Form 4, code S).
- Feb 18, 2026: Grants or awards of SUPN derivative securities (2 lines, Form 4, code A).
Other insiders filing for KalVista Pharmaceuticals, Inc. (KALV)
- Stuart Nancy, Director
- Pereira Brian JG, Director
- Fairey William, Director
- Audhya Paul K., CHIEF MEDICAL OFFICER
- Treanor Patrick, Director
- Sweeny Nicole, Chief Commercial Officer